METAVERSE WORLD FAKE WORLD

[mick]

***** https://seekingalpha.com/symbol/PPCB --- $0.0007 , HEALTHCARE CURRENT LOW
SHARE COUNT
https://www.otcmarkets.com/stock/PPCB
52 WK HIGH LOW 0.0005 - 0.045
http://www.propanc.com/news-media/video.
http;//www.propanc.com
https://www.propanc.com/about
https://www.propanc.com/product-pipeline
https://www.propanc.com/technology
https://www.propanc.com/news-media
https://ir.propanc.com/historical-data
Outstanding Shares 889,745,790
11/09/2022
Restricted 121,053,807
11/09/2022
Unrestricted 768,691,983
11/09/2022
Held at DTC 768,654,125
11/09/2022
Float 100,616,724
05/17/2022
MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc.
(OTC Pink: PPCB) (“Propanc” or the “Company”),
a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring
and metastatic cancer, today announced that the Company’s Joint Researcher,
Mrs. Belén Toledo Cutillas, MSc, at the laboratory of Professor Macarena Perán, PhD, University of Jaén, Spain, received an award for best poster at the
“Doctoral Days 2022 for Young Researchers of the University of Jaén,” conference.

The poster, entitled, “Blocking Tumor Support from Cancer Associated Fibroblasts in Tumor